Sequences_of_taxol_and_cisplatin:_a_phase_I_and_pharmacologic_study._Untreated_and_minimally_pretreated_solid_tumor_patients_received_alternating_sequences_of_taxol_and_cisplatin._Sequential_dose_escalation_of_each_agent_using_taxol_doses_of_110_or_135_mg/m2_and_cisplatin_doses_of_50_or_75_mg/m2_resulted_in_four_dosage_permutations_that_induced_grades_3_and_4_neutropenia_in_72%_to_84%_and_50%_to_53%_of_courses,_respectively._Neutropenia_was_brief,_and_hospitalization_for_neutropenia_and_fever_was_required_in_13%_to_24%_of_courses._However,_further_escalation_of_taxol_to_170_or_200_mg/m2_induced_grade_4_neutropenia_in_79%_to_82%_of_courses._At_the_highest_taxol-cisplatin_dose_level_(200_mg/m2_to_75_mg/m2),_the_mean_neutrophil_count_nadir_was_98/microL,_and_hospitalization_for_neutropenia_and_fever_was_required_in_64%_of_courses._The_sequence_of_cisplatin_before_taxol,_which_has_less_antitumor_activity_in_vitro,_induced_more_profound_neutropenia_than_the_alternate_sequence._Pharmacologic_studies_indicated_that_this_difference_was_probably_due_to_25%_lower_taxol_clearance_rates_when_cisplatin_preceded_taxol._Although_neurotoxicity_was_initially_thought_to_be_a_potentially_serious_effect_of_the_combination,_mild_to_modest_neurotoxicity_occurred_in_only_27%_of_patients._Adverse_effects_also_included_myalgias,_alopecia,_vomiting,_diarrhea,_bradycardia,_and_asymptomatic_ventricular_tachycardia._Objective_responses_were_noted_in_melanoma,_as_well_as_non-small-cell_lung,_ovarian,_breast,_head_and_neck,_colon,_and_pancreatic_carcinomas._Based_on_these_results,_the_sequence_of_taxol_before_cisplatin_at_doses_of_135_and_75_mg/m2,_respectively,_is_recommended_for_phase_II/III_trials,_with_escalation_of_taxol_to_170_mg/m2_if_treatment_is_well_tolerated.